Phase 2 Pulmonary Hypertension Trial, Recruiting NCT06053580 Sponsor: University of Washington Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 2 Pulmonary Hypertension Trial, Recruiting

NCT06053580
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old (male or female)
  • You have been diagnosed with a specific type of high blood pressure in the lungs called WHO Group 1 Pulmonary Arterial Hypertension
  • Your symptoms fall into a moderate to severe category based on how much your condition limits your daily activities (confirm with trial site)
  • You have had a special heart test (a tube inserted near the heart to measure pressures) within the last five years showing certain elevated pressure and resistance readings in your lung blood vessels
  • You may also qualify if your heart test showed slightly different pressure readings, but only if your resistance level is high enough and you are already being treated for pulmonary arterial hypertension (confirm with trial site)
  • You are able to walk at least 50 meters (roughly half a football field) with or without a walking aid

Who may not be able to join:

  • You are currently pregnant or breastfeeding
  • Your lung high blood pressure is caused by something other than WHO Group 1, or you have a condition called veno-occlusive disease
  • You have a history of scarring or inflammation of the lungs (interstitial lung disease), unless you have a connective tissue disease and recent lung function tests show your lung capacity is at least 60%
  • You have taken part in, or plan to take part in, another clinical trial or use an experimental treatment within 30 days of joining or during this study
  • You have taken certain blood pressure medications called ACE-inhibitors, ARBs, or ARNIs within 30 days of being assigned to a treatment group
  • You have a weakened left side of the heart, where the heart is pumping less than 40% of its normal capacity
  • You have any other serious illness or abnormal blood test results that the study doctor believes could put you at risk or affect the study results
  • Your doctors expect you may not survive longer than one year due to another serious illness
  • You have had a severe allergic reaction or dangerous swelling (angioedema) caused by ACE-inhibitor medications
  • Your blood potassium levels or kidney function values are above certain limits at your screening appointment (confirm specific values with trial site)
  • Your resting blood pressure is below 90 mmHg (considered low blood pressure) at your screening appointment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Peter Leary, MD, PhD, University of Washington

Phone: 206.543.8334

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
28 February 2024
Est. completion
1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Six-minute walk distance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov